Factors controlling the effect of praziquantel on liver fibrosis inSchistosoma mansoni-infected patients
| Autor: | Siddig A. Rahoud, Nasr Eldin Elwali, Osman K. Saeed, Adil Mergani, Alain Dessein, Ammar H. Khamis, Qurashi Mohamed-Ali |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Liver Cirrhosis Male Microbiology (medical) medicine.medical_specialty Pathology Adolescent Liver Diseases Parasitic Immunology Microbiology Gastroenterology Praziquantel Sudan Young Adult Sex Factors Fibrosis Internal medicine medicine Animals Humans Immunology and Allergy Anthelmintic Child Ultrasonography Anthelmintics biology Portal Vein Age Factors Schistosoma mansoni General Medicine Middle Aged biology.organism_classification medicine.disease Schistosomiasis mansoni Treatment Outcome Infectious Diseases Liver Splenic vein Child Preschool Cohort Disease Progression Female Hepatic fibrosis medicine.drug Cohort study |
| Zdroj: | FEMS Immunology & Medical Microbiology. 58:106-112 |
| ISSN: | 1574-695X 0928-8244 |
| DOI: | 10.1111/j.1574-695x.2009.00640.x |
| Popis: | An association study of a cohort of 177 Sudanese patients infected with Schistosoma mansoni [82 (46%) males and 95 (54%) females] was conducted to evaluate the factors controlling the regression of liver fibrosis 39 months after treatment with praziquantel using ultrasound evaluation. Periportal fibrosis (PPF) was regressed in 63 (35.6%) patients, while the disease progressed to higher grades in 24 (13.6%) patients. The grade of PPF did not change in 90 (50.8%) patients. The mean values of portal vein diameter, splenic vein diameter and index liver size in subjects in whom PPF regressed after treatment were significantly lower than in subjects in whom the disease was progressed (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text